Login / Signup

Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression.

Phyllis F CheungJiaJin YangRui FangArianna BorgersKirsten KrengelAnne StoffelKristina AlthoffChi Wai YipElaine H L SiuLinda W C NgKarl S LangLamin B ChamDaniel R EngelCamille SounIgor CimaBjörn SchefflerJana K StrieflerMarianne SinnMarcus BahraUwe PelzerHelmut OettlePeter MarkusEsther M M SmeetsErik H J G AarntzenKonstantinos SavvatakisSven-Thorsten LiffersSmiths S LueongChristian NeanderAnna BazarnaXin ZhangAnnette PaschenHoward C CrawfordAnthony W H ChanSiu Tim CheungJens Thomas Siveke
Published in: Nature communications (2022)
Immune evasion is indispensable for cancer initiation and progression, although its underlying mechanisms in pancreatic ductal adenocarcinoma (PDAC) are not fully known. Here, we characterize the function of tumor-derived PGRN in promoting immune evasion in primary PDAC. Tumor- but not macrophage-derived PGRN is associated with poor overall survival in PDAC. Multiplex immunohistochemistry shows low MHC class I (MHCI) expression and lack of CD8 + T cell infiltration in PGRN-high tumors. Inhibition of PGRN abrogates autophagy-dependent MHCI degradation and restores MHCI expression on PDAC cells. Antibody-based blockade of PGRN in a PDAC mouse model remarkably decelerates tumor initiation and progression. Notably, tumors expressing LCMV-gp33 as a model antigen are sensitized to gp33-TCR transgenic T cell-mediated cytotoxicity upon PGRN blockade. Overall, our study shows a crucial function of tumor-derived PGRN in regulating immunogenicity of primary PDAC.
Keyphrases